Viking Therapeutics Announces Positive Top-Line Results from

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo
Up to 13.1% Placebo-Adjusted Mean Weight...

Related Keywords

, Drug Administration , Nasdaq , Ligand Pharmaceuticals Incorporated , Therapeutics Inc , Study Achieves Primary , Secondary Endpoints , Body Weight , Placebo Adjusted Mean Weight Loss , From Baseline , Observed After , Week Study , Treatment Emergent Adverse Events Considered Mild , Call Scheduled , Viking Therapeutics , Body Weight Following , Once Weekly Dosing , Common Gastrointestinal , Ligand Pharmaceuticals , Markets ,